These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24896823)

  • 1. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
    Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
    PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging ligand-dependent activation of CXCR7.
    Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
    Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
    Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
    Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
    Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
    J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
    Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
    Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration.
    Décaillot FM; Kazmi MA; Lin Y; Ray-Saha S; Sakmar TP; Sachdev P
    J Biol Chem; 2011 Sep; 286(37):32188-97. PubMed ID: 21730065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMD3100 is a CXCR7 ligand with allosteric agonist properties.
    Kalatskaya I; Berchiche YA; Gravel S; Limberg BJ; Rosenbaum JS; Heveker N
    Mol Pharmacol; 2009 May; 75(5):1240-7. PubMed ID: 19255243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR7 as a novel therapeutic target for advanced prostate cancer.
    Gritsina G; Yu J
    Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.
    Torossian F; Anginot A; Chabanon A; Clay D; Guerton B; Desterke C; Boutin L; Marullo S; Scott MG; Lataillade JJ; Le Bousse-Kerdilès MC
    Blood; 2014 Jan; 123(2):191-202. PubMed ID: 24277075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
    Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
    Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
    Odemis V; Lipfert J; Kraft R; Hajek P; Abraham G; Hattermann K; Mentlein R; Engele J
    Glia; 2012 Mar; 60(3):372-81. PubMed ID: 22083878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Nazari A; Khorramdelazad H; Hassanshahi G
    Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
    Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
    J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
    Xu D; Li R; Wu J; Jiang L; Zhong HA
    Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
    Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
    Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
    Costantini S; Raucci R; De Vero T; Castello G; Colonna G
    Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.
    Oishi S; Kuroyanagi T; Kubo T; Montpas N; Yoshikawa Y; Misu R; Kobayashi Y; Ohno H; Heveker N; Furuya T; Fujii N
    J Med Chem; 2015 Jul; 58(13):5218-25. PubMed ID: 26042340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
    Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
    Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4.
    Uto-Konomi A; McKibben B; Wirtz J; Sato Y; Takano A; Nanki T; Suzuki S
    Biochem Biophys Res Commun; 2013 Feb; 431(4):772-6. PubMed ID: 23333329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.